Castro Beatriz Guerreiro Ruiz, Souza Cristiano de Pádua, Andrade Carlos Eduardo Mattos da Cunha, Vieira Marcelo de Andrade, Andrade Diocésio Alves Pinto de, Reis Ricardo Dos
Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata, Barretos, SP, Brazil.
Gynecologic Clinical Oncology Department, Hospital do Câncer de Barretos, Barretos, SP, Brazil.
Rev Bras Ginecol Obstet. 2019 Jul;41(7):440-448. doi: 10.1055/s-0039-1693056. Epub 2019 Jul 25.
To describe a series of cases of ovarian Sertoli-Leydig cell tumors (SLCTs).
Retrospective review of 12 cases of SLCT treated at the Hospital do Câncer de Barretos, Barretos, state of São Paulo, Brazil, between October 2009 and August 2017.
The median age of the patients was 31 years old (15-71 years old). A total of 9 patients (75.0%) presented symptoms: 8 (66.7%) presented with abdominal pain, 5 (41.7%) presented with abdominal enlargement, 2 (16.7%) presented with virilizing signs, 2 (16.7%) presented with abnormal uterine bleeding, 1 (8.3%) presented with dyspareunia, and 1 (8.3%) presented with weight loss. The median preoperative lactate dehydrogenase (LDH) was 504.5 U/L (138-569 U/L), alpha-fetoprotein (AFP) was 2.0 ng/ml (1.1-11.3 ng/ml), human chorionic gonadotropin (β-hCG) was 0.6 mUI/ml (0.0-2.3 mUI/ml), carcinoembryonic antigen (CEA) was 0.9 ng/ml (0.7-3.4 ng/ml), and cancer antigen 125 (CA-125) was 26.0 U/ml (19.1-147.0 U/ml). All of the tumors were unilateral and surgically treated. Lymphadenectomy was performed in 3 (25.0%) patients, but none of the three patients submitted to lymphadenectomy presented lymph node involvement. In the anatomopathological exam, 1 (8.3%) tumor was well-differentiated, 8 (66.7%) were moderately differentiated, and 3 (25.0%) were poorly differentiated. A total of 5 (55.6%) tumors were solid-cystic, 2 (22.2%) were purely cystic, 1 (11.1%) was cystic with vegetations, and 1 (11.1%) was purely solid, but for 3 patients this information was not available. The median lesion size was 14.2 cm (3.2-23.5 cm). All of the tumors were at stage IA of the 2014 classification of the International Federation of Gynecology and Obstetrics (FIGO). A total of 2 (16.7%) patients received adjuvant treatment; 1 of them underwent 3 cycles of paclitaxel and carboplatin every 21 days, and the other underwent 4 cycles of ifosfamide, cisplatin and etoposide every 21 days. None of all of the patients had recurrence, and one death related to complications after surgical staging occurred.
Abdominal pain was the most frequent presentation. There was no ultrasonographic pattern. All of the SLCTs were at stage IA, and most of them were moderately differentiated. Relapses did not occur, but one death related to the surgical staging occurred.
描述一系列卵巢支持-间质细胞瘤(SLCT)病例。
回顾性分析2009年10月至2017年8月期间在巴西圣保罗州巴雷图斯科癌症医院接受治疗的12例SLCT病例。
患者的中位年龄为31岁(15 - 71岁)。共有9例患者(75.0%)出现症状:8例(66.7%)表现为腹痛,5例(41.7%)表现为腹部增大,2例(16.7%)表现为男性化体征,2例(16.7%)表现为子宫异常出血,1例(8.3%)表现为性交困难,1例(8.3%)表现为体重减轻。术前乳酸脱氢酶(LDH)的中位值为504.5 U/L(138 - 569 U/L),甲胎蛋白(AFP)为2.0 ng/ml(1.1 - 11.3 ng/ml),人绒毛膜促性腺激素(β-hCG)为0.6 mUI/ml(0.0 - 2.3 mUI/ml),癌胚抗原(CEA)为0.9 ng/ml(0.7 - 3.4 ng/ml),癌抗原125(CA - 125)为26.0 U/ml(19.1 - 147.0 U/ml)。所有肿瘤均为单侧并接受了手术治疗。3例(25.0%)患者进行了淋巴结清扫,但接受淋巴结清扫的3例患者均未出现淋巴结受累。在病理检查中,1例(8.3%)肿瘤为高分化,8例(66.7%)为中分化,3例(25.0%)为低分化。共有5例(55.6%)肿瘤为实性-囊性,2例(22.2%)为纯囊性,1例(11.1%)为有赘生物的囊性,1例(11.1%)为纯实性,但3例患者的此信息未提供。病变的中位大小为14.2 cm(3.2 - 23.5 cm)。所有肿瘤均处于国际妇产科联盟(FIGO)2014年分类的IA期。共有2例(16.7%)患者接受了辅助治疗;其中1例每21天接受3个周期的紫杉醇和卡铂治疗,另1例每21天接受4个周期的异环磷酰胺、顺铂和依托泊苷治疗。所有患者均未复发,1例患者在手术分期后因并发症死亡。
腹痛是最常见的表现。没有超声特征性表现。所有SLCT均处于IA期,且大多数为中分化。未发生复发,但有1例与手术分期相关的死亡。